Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810144 · ClinicalTrials.gov registry record
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 444
- Enrollment target
NCT03810144 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 444 participants.
The verdict
NCT03810144 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 444 participants
- Enrollment target
Study Summary
Nine months multi-center prospective, randomized observational study, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs.
Interventions
- GENETIC Vectra MBDA Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2022-10-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03810144
The ClinicalTrials.gov registry entry for NCT03810144 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vectra MBDA Test is the first listed.
NCT03810144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03810144 about?
NCT03810144 is a clinical study titled "Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test". Nine months multi-center prospective, randomized observational study, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs.
What is the current status of trial NCT03810144?
This trial is currently completed. The enrollment target is 444 participants. The study started on 2018-10-22. Estimated completion is 2022-10-16.
What interventions are being tested in trial NCT03810144?
The interventions under investigation include: Vectra MBDA Test (GENETIC).
Who is sponsoring clinical trial NCT03810144?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.